Beta-Blockers: What They Do and Who Needs Them

Starting or staying on a beta-blocker: what to do next

Beta-blockers are long-term medicines for most people who take them. Use this as a checklist for conversations with your doctor, not as medical advice:

Beta-blocker formulations: immediate vs extended release

Several beta-blockers come in more than one form. The table below describes the forms available — which form and strength you take is your doctor's decision.

Which beta-blocker for which condition?

Beta-blockers differ in their selectivity for cardiac (beta-1) versus lung/vascular (beta-2) receptors, and in having additional properties:

• Bisoprolol / metoprolol / atenolol: cardioselective (mainly beta-1); preferred in heart failure (bisoprolol), hypertension, and after heart attack. At higher doses, selectivity is lost.
• Carvedilol: non-selective beta-blocker plus alpha-1 blocker; used in heart failure (with proven mortality benefit) and hypertension. Causes more vasodilation than cardioselective agents.
• Propranolol: non-selective; used for tremor, anxiety, migraine prevention, thyrotoxicosis, and portal hypertension. Higher risk of bronchospasm.
• Labetalol: used in hypertension in pregnancy (alpha+beta blocker).
• Sotalol: rate control in atrial fibrillation, with additional rhythm-stabilising effects.

Never stop beta-blockers suddenly: why it matters

Stopping abruptly can trigger rebound hypertension, unstable angina, or even a heart attack. This happens because the body upregulates (increases the number of) beta-adrenergic receptors during beta-blocker therapy. When the drug is suddenly withdrawn, these extra receptors respond to circulating adrenaline more powerfully than normal, dramatically increasing heart rate and blood pressure.

If a beta-blocker must be stopped, for example before surgery, it should be tapered gradually whenever possible, with the pace agreed with your doctor. If an urgent stop is unavoidable, close cardiovascular monitoring is needed in the days immediately after.

Beta-blockers and asthma: a critical caution

Non-selective beta-blockers (propranolol, carvedilol) are contraindicated in asthma because blocking beta-2 receptors in the bronchial smooth muscle causes bronchoconstriction. Even cardioselective agents (bisoprolol, metoprolol) carry a relative contraindication and should only be used in asthma when there is a compelling cardiac indication, at the lowest effective amount, with close monitoring for worsening breathlessness or wheeze.

Patients with COPD (not asthma) can usually tolerate cardioselective beta-blockers, and the mortality benefit in heart failure typically outweighs the small risk of worsening airflow obstruction.

Monitoring on beta-blockers

Side effects

• Fatigue and tiredness: very common
• Cold hands and feet
• Slower heart rate (bradycardia)
• Worsening breathlessness (especially in asthma)
• Vivid dreams / nightmares (especially propranolol)
• Erectile dysfunction
• Masks hypoglycaemia symptoms in diabetics

Pharmacist's practical notes

Ask your doctor what heart rate and blood pressure ranges to watch for at home, and report a persistently very slow pulse, unusual fatigue, cold hands and feet that are new, wheezing, or swelling. The single most important rule with beta-blockers is never to stop them suddenly — abrupt stopping can trigger rebound high blood pressure, chest pain, or rhythm problems. Any change must be tapered on a doctor’s plan.

Tell every prescriber you take a beta-blocker, because several common medicines interact: certain other heart-rate-lowering medicines, some calcium channel blockers, and clonidine need careful handling. If you have diabetes, mention it — beta-blockers can mask the warning signs of low blood sugar such as a racing heartbeat. Keep a full medicine list including inhalers and over-the-counter cold remedies.

Because sudden stopping is risky, a missed dose should be handled by asking your pharmacist rather than doubling up or skipping ahead. Some beta-blockers come as extended-release tablets that must be swallowed whole — if swallowing is difficult, ask your pharmacist before crushing or splitting anything. Store at room temperature away from moisture.

Tell your anaesthetist and surgical team about your beta-blocker before any operation; it is usually continued through surgery, and stopping without the team’s knowledge can be dangerous. Also mention it before any new diagnosis of asthma or breathing trouble, since wheezing on a beta-blocker needs prompt medical review.

In India

Common beta-blockers such as metoprolol, atenolol, and propranolol are widely prescribed in India, and generic versions are typically inexpensive, though prices vary by brand and city.

They are available on prescription at pharmacies across India. Follow your own prescription; never start, stop, or change a dose without your doctor.

Frequently Asked Questions

How Beta-Blockers Work and Which Conditions They Treat

Beta-blockers (beta-adrenoceptor antagonists) block the binding of adrenaline (epinephrine) and noradrenaline to beta-adrenergic receptors, reducing heart rate, myocardial contractility, and, in higher doses, peripheral vascular resistance. Cardioselective beta-blockers (bisoprolol, metoprolol, atenolol) primarily block β1-receptors in the heart; non-selective agents (propranolol, carvedilol) block both β1 and β2 receptors, also affecting bronchial smooth muscle and peripheral vasodilation.

The evidence base for beta-blockers spans multiple conditions. In heart failure with reduced ejection fraction (HFrEF), landmark placebo-controlled trials of bisoprolol, carvedilol, and sustained-release metoprolol have each found a relative reduction in all-cause mortality of around 34–35%, one of the largest mortality benefits of any drug class in cardiovascular medicine. In the pivotal carvedilol trial, which enrolled patients with severe heart failure (ejection fraction under 25%), carvedilol reduced all-cause mortality by 35% compared with placebo (130 deaths versus 190 over a mean follow-up of 10.4 months).¹ In hypertension, they lower blood pressure through reduced cardiac output and, with chronic use, by resetting baroreceptor sensitivity. In angina, they reduce myocardial oxygen demand by limiting exercise-induced heart rate increases. They are first-line for rate control in atrial fibrillation and essential for secondary prevention post-myocardial infarction.

Blood Tests Required Before and During Beta-Blocker Treatment

Beta-blockers do not directly cause the laboratory abnormalities that some other cardiac drugs do, but monitoring is still structured around the conditions they treat. Before starting, baseline renal function (creatinine, eGFR) and electrolytes (potassium, sodium) are essential, hyperkalaemia can be worsened when beta-blockers are combined with ACE inhibitors, ARBs, or spironolactone, which is common in heart failure. Thyroid function (TSH) is checked because hyperthyroidism drives tachycardia and atrial fibrillation, and beta-blockers are used to control symptoms while definitive treatment is arranged; normalising thyroid function changes the dose required.

In people with diabetes, beta-blockers mask some of the sympathetic warning signs of hypoglycaemia (tremor, palpitations) while leaving sweating intact. Blood glucose monitoring becomes more important, and HbA1c testing every three months helps detect worsening glycaemic control. Liver function tests are relevant for propranolol, which is extensively hepatically metabolised; impaired liver function increases exposure and risk of bradycardia.

Side Effects That Show Up in Blood Tests

Most beta-blocker side effects are haemodynamic (bradycardia, hypotension, fatigue, cold extremities) rather than metabolic, but some laboratory changes are clinically significant. Beta-blockers as a class tend to raise triglycerides, a meta-analysis of over 65,000 patients across 474 trials found an average rise of 0.35 mmol/L (about 31 mg/dL), an effect that was substantially smaller for agents with intrinsic sympathomimetic activity, and can modestly lower HDL cholesterol.³ This is relevant when monitoring cardiovascular risk in patients already on a statin. Serum potassium requires periodic checking in patients on combination heart failure therapy, as the combination of beta-blocker, ACE inhibitor, and spironolactone carries hyperkalaemia risk. Creatinine and eGFR should be rechecked after any dose titration in patients with pre-existing chronic kidney disease, as reduced cardiac output from the drug can lower renal perfusion.